BofA Securities Maintains Bluebird Bio(BLUE.US) With Buy Rating

BofA Securities analyst Jason Gerberry maintains $bluebird bio(BLUE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.4% and a total average return of -0.6%

Moomoo NewsJul 10 09:33 ET · Ratings

Bluebird Bio (BLUE) Gets a Buy From Bank of America Securities

TipRanksJul 10 09:17 ET

Bluebird Bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)

bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to

BusinesswireJul 3 16:05 ET

2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare...

PR NewswireJun 2 22:15 ET

BioLineRx Stock Jumps 14% on St. Jude Clinical Trial for Mitoxafortide

Seeking AlphaMay 30 13:54 ET

Bluebird Bio Announces CFO Transition and Compensation Details

TipRanksMay 29 08:50 ET